Cobas C Tina-Quant Lipoprotein (A) Gen 2 Assay Model 05852625190 and 1 more
Lipoprotein, Low-Density, Antigen, Antiserum, Control. 510(k) K122722, from Roche Diagnostics (Indianapolis, IN). Product code DFC, class 2.
As of Nov 20, 2026, K122722 is an FDA 510(k) held by Roche Diagnostics, substantially equivalent on Nov 29, 2012 after 85 days, with no recalls tied to it in FDA's recall database.
- Review time: 85 days
- Recalls: 0
- Cited as a predicate by: 1 device
The cobas c Tina-quant Lipoprotein (a) Gen.2 assay is an in vitro test intended for the quantitative determination of lipoprotein(a) [Lp(a)] in human serum and plasma on the Roche/Hitachi cobas c systems.
- LP(A)-Latex Seiken Assay KitK013359 · Denka Seiken'S · Mar 8, 2002
- Diazyme LP(A) AssayK082488 · General Atomics · Jan 13, 2009
- Tina-quant Lipoprotein(a) Gen.2 MolarityK241220 · Roche Diagnostics Operations · Jan 24, 2025
- Lipoprotein (a) Molarity AssayK253069 · Diazyme Laboratories, Inc. · Jun 16, 2026
- Tina-quant Lipoprotein(a) Gen.2 MolarityK241220 · Roche Diagnostics Operations · Jan 24, 2025
- Lp(a) UltraK211058 · SENTINEL CH. SpA · Dec 22, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Sep 5, 2012
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5600
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files